TICKERNERD
Menu
PBMPBMHealthcare · Biotechnology

PBM Stock Forecast: Psyence Biomedical Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.40

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap
$20.6M
Ticker Nerd rank
4 / 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$1.5M
Net income−$753K
Quarterly, 4 quarters to 30 Sept 2025 · latest quarter's figure shown
Ticker Nerd rank

PBM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Psyence Biomedical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Momentum
29
Revisions
25
Issuance
22
Growth
8
Accruals
8
Volatility
7
Quality
4
Value
4

Size (88): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PBM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBM, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PBM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Psyence Biomedical Ltd. (PBM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
−2.1×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−58.6%

Higher than 19% of US stocks

Return on assets
−31.3%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Psyence Biomedical Ltd. (PBM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Psyence Biomedical Ltd. has a market value of $20.6M and an enterprise value of $13.2M.

  • Revenue in the twelve months to 30 Sept 2025: $0.0.

  • Net income over the same four quarters: −$1.1M.

  • Diluted earnings per share, trailing twelve months: $6.29.

  • Shares outstanding: 299,528.

  • Trailing P/E: 0.0×.

  • Psyence Biomedical Ltd. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 Sept 2025 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

PBM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PBMPsyence Biomedical Ltd.$20.6M
4
TCRXTScan Therapeutics, Inc.$20.9M
51
GRDXGridAI Technologies Corp.$20.3M
18
PTNPalatin Technologies, Inc.$20.1M
33
NEUPNeuphoria Therapeutics, Inc.$20.1M
5
KRSAKorsana Biosciences, Inc.$21.3M
42
ALLRAllarity Therapeutics, Inc.$19.6M
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Psyence Biomedical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBM news & analysis

Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development

GlobeNewsWire · 18 Aug 2026positive

Psyence BioMed welcomed the U.S. administration's latest action to accelerate ibogaine development. The company stated that the growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform it has built.

Why it matters — A watcher of Psyence BioMed would care because increased federal support for ibogaine development could align with and potentially benefit the company's existing pharmaceutical platform.

FAQ

Frequently asked questions about PBM stock

How does Ticker Nerd's model rank PBM?

As at 12 Sept 2026, Psyence Biomedical Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

What is the PBM stock forecast for 2030?

No analyst covering Psyence Biomedical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBM are extrapolating price history, which says nothing about the business.

What does Psyence Biomedical Ltd. do?

Psyence Biomedical Ltd. is a Toronto-based biopharmaceutical company focused on developing botanical psilocybin-based medicines for mental health and palliative care settings.

What is the latest news on PBM?

The most recent item we track (GlobeNewsWire, 18 Aug 2026): "Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development". Psyence BioMed welcomed the U.S. administration's latest action to accelerate ibogaine development. The company stated that the growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform it has built.

Company

About Psyence Biomedical Ltd.

Psyence Biomedical Ltd. is a Toronto-based biopharmaceutical company focused on developing botanical psilocybin-based medicines for mental health and palliative care settings. The company’s current work centers on nature-derived psychedelic therapeutics designed to address unmet needs in conditions such as adjustment disorder, anxiety, depression, grief, and related psychological distress in patients facing serious illness. Its lead candidate is being evaluated in clinical studies as a capsule formulation of naturally sourced psilocybin, reflecting the company’s emphasis on standardized, non-synthetic drug development. Psyence Biomedical operates within the broader life sciences and healthcare markets, combining drug development, clinical research, and commercialization efforts around psychedelic medicine. Through this specialization, the company occupies a niche position in the emerging field of evidence-based psychedelic therapeutics, with a focus on supportive care applications rather than general consumer health products.

CEO Mr. Jody Aufrichtig · 12 employees · Canada · https://psyencebiomed.com